Skip to main content
TipRanks
Go Ultimate75% OFF

DKSH Holding AG (DKSH) AI Stock Analysis

8 Followers
CH:DKSH

DKSH Holding AG

(Six Swiss:DKSH)

Select Model
Rating:62Neutral
Price Target:CHF 83.00â–²(5.60% Upside)
Action:reiterated
Date:10/17/26

The score is driven mainly by stable but low-margin financials with reliable (though sometimes volatile) cash generation, supported by a constructive earnings outlook and strong recent cash conversion. Technicals are positive but appear somewhat overextended, while valuation is only moderately attractive given a ~21x P/E despite a healthy ~3.5% dividend.

Positive Factors
Strong H1 growth and earningsDKSH’s strongest first-half revenue growth in three years, combined with double-digit profit expansion, indicates improving commercial execution and product demand. Continued growth across markets can strengthen operating leverage, support reinvestment, and improve earnings durability over the next several quarters.
Negative Factors
Structurally thin profitabilityDKSH’s high-volume distribution model produces consistently low margins, so modest cost increases, adverse mix, or execution issues can materially affect earnings. Thin profitability limits the cushion available during weaker demand and makes sustained margin improvement important for durable returns.

DKSH Holding AG (DKSH) vs. iShares MSCI Switzerland ETF (EWL)

-10%0%10%20%30%40%50%60%CH:DKSH+50.55%EWL+16.85%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 5.11B
Dividend Yield
3.18%
Average Volume (3M)
79.22K
Price to Earnings (P/E)
23.3
Beta (1Y)
0.90
Revenue Growth
-1.37%
EPS Growth
8.55%
Country
Switzerland
Employees
24,942
Sector
General
Sector Strength
55
Industry
Consulting Services

DKSH Holding AG Business Overview & Revenue Model

Company Description

DKSH Holding AG provides various market expansion services in Thailand, Greater China, Malaysia, Singapore, rest of the Asia Pacific, and internationally. The company offers sourcing, market insights, marketing, sales, e-Commerce, distribution, logis...

How the Company Makes Money

DKSH makes money primarily by providing market expansion services to client companies and earning fees and margins tied to the sale and distribution of those clients’ products across Asian markets. Key revenue streams typically include: (1) Distribut...

DKSH Holding AG Earnings Call Summary

Earnings Call Date:Jul 17, 2026(Q2-2026)|% Change Since:16.27%|Next Earnings Date:Feb 16, 2027
Earnings Call SentimentPositive

Overall the call conveyed a constructive and confident view: the company delivered its strongest first‑half top‑line growth in three years, double‑digit EPS growth, excellent cash generation and progress across strategic priorities (M&A, AI, sustainability). Challenges highlighted were primarily translational FX headwinds and temporary margin pressure from deliberate investments and ramp‑ups (healthcare, AI and marketing). Management reiterated confidence in a stronger second half, a robust M&A pipeline, and medium‑term margin expansion.

Positive Updates

Revenue Growth — Strongest H1 in Three Years
Net sales increased 4.9% to CHF 5.5 billion (constant FX), representing the company's strongest first-half revenue growth in three years.

Negative Updates

Core EBIT Margin Slight Decline and Temporary Margin Pressure
Group Core EBIT margin fell slightly to 3.0% (down ~10 basis points year-over-year). Management attributed the decline to translational FX headwinds and temporary operational investments (AI, business development, ramp-up costs) that pressured margins in H1.

Company Guidance

DKSH guided that Core EBIT for 2026 is expected to be higher than in 2025, while flagging a moderately negative translational FX impact for the full year if exchange rates remain broadly unchanged; management expects acquisitions announced/completed to date to add roughly +1 percentage point to 2026 net sales, foresees capex of ~0.3–0.4% of net sales and a tax rate of 27–29%, is targeting a modest Core EBIT margin improvement (around +10 bps), expects a double‑digit full‑year profit contribution from associates (data‑center projects) by year‑end, and reiterated confidence in stronger H2 momentum driven by AI, data‑center growth and accelerated M&A—supported by strong cash generation (H1 free cash flow CHF 147.7m; cash conversion 130.8%).

DKSH Holding AG Financial Statement Overview

Summary

Mid-range fundamentals: income statement stability but thin margins (net ~1.6–2.0%, operating ~2.3–3.1%) and limited growth, with a notable 2025 revenue/FCF drop flagged as a key uncertainty. Balance sheet is solid with manageable leverage (debt-to-equity ~0.32–0.58) and consistent ROE (~9–12%), though leverage has trended higher. Cash flow is reliably positive (OCF ~CHF 322–393M; FCF ~CHF 237–341M) with decent earnings conversion, but FCF growth has been volatile (including sharp weakness in 2025).

Income Statement

56Neutral

Balance Sheet

62Positive

Cash Flow

58Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue11.02B11.07B11.09B11.07B11.32B11.11B
Gross Profit661.90M746.90M1.64B1.65B792.80M770.50M
EBITDA420.90M438.30M472.00M434.90M437.30M460.60M
Net Income212.20M202.90M214.80M182.00M201.10M223.90M
Balance Sheet
Total Assets5.55B5.50B5.85B5.47B5.88B5.35B
Cash, Cash Equivalents and Short-Term Investments503.70M538.40M609.10M687.20M636.40M673.70M
Total Debt762.50M753.00M839.80M958.20M1.01B587.10M
Total Liabilities3.78B3.68B3.97B3.73B4.05B3.46B
Stockholders Equity1.71B1.76B1.82B1.69B1.76B1.81B
Cash Flow
Free Cash Flow308.60M281.90M321.30M340.80M237.00M338.20M
Operating Cash Flow339.30M320.10M362.90M393.10M321.90M393.20M
Investing Cash Flow-106.30M-99.70M-75.60M-116.50M-511.80M-147.90M
Financing Cash Flow-209.20M-267.60M-364.20M-185.20M180.70M-239.50M

DKSH Holding AG Technical Analysis

Technical Analysis SentimentPositive
Last Price78.60

Price Trends

50DMA72.00Positive
100DMA69.12Positive
200DMA64.33Positive

Market Momentum

MACD1.86Positive
RSI70.88Negative
STOCH85.28Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:DKSH, the sentiment is Positive. The current price of 78.60 is above the 20-day moving average (MA) of 77.28, above the 50-day MA of 72.00, and above the 200-day MA of 64.33, indicating a bullish trend. The MACD of 1.86 indicates Positive momentum. The RSI at 70.88 is Negative, neither overbought nor oversold. The STOCH value of 85.28 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:DKSH.

DKSH Holding AG Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

CH:DKSH against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CH:BELLCH:BELL72OutperformCHF 1.66B20.874.90%2.65%1.67%-36.08%
CH:GALECH:GALE70OutperformCHF 4.55B28.65―2.74%6.48%-17.25%
CH:KARNCH:KARN70OutperformCHF 1.86B72.00―2.48%2.60%-65.24%
CH:KNINCH:KNIN66NeutralCHF 27.84B28.55―2.56%1.09%-5.24%
CH:DKSHCH:DKSH62NeutralCHF 5.11B23.25―3.18%-1.37%8.55%
CH:SIGNCH:SIGN62NeutralCHF 5.89B-151.71-1.59%―-4.89%-122.68%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%

* General Sector Average

Performance Comparison

-20%0%20%40%60%CH:DKSHCH:KNINCH:KARNCH:BELLCH:SIGNCH:GALEDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:DKSH and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:DKSHDKSH Holding78.6026.4950.82%
CH:KNINKuehne + Nagel234.4087.6059.67%
CH:KARNKardex AG241.50-19.76-7.56%
CH:BELLBell Food Group 264.0045.4620.80%
CH:SIGNSIG Group AG15.426.6575.83%
CH:GALEGalenica AG91.406.828.06%

DKSH Holding AG Corporate Events

DKSH Advances Women’s Health Equity Through Global Patient Initiative

Nov 4, 2026

DKSH Business Unit Healthcare is an integrated healthcare commercialization and distribution partner serving Asia Pacific and other international markets. Its services cover pharmaceuticals, consumer health products, medical devices, market expansion...

DKSH Ranks 21st Among Southeast Asia’s Best Workplaces

Nov 3, 2026

DKSH, a market expansion services provider for companies seeking growth in Asia and beyond, ranked 21st in Fortune’s 2026 list of the 100 Best Companies to Work For in Southeast Asia. The recognition marks its second consecutive appearance and highli...

DKSH Secures CHF 100 Million Sustainability-Linked Loan

Nov 3, 2026

DKSH is a Market Expansion Services provider serving companies across Asia Pacific, Europe, and North America through its Healthcare, Consumer Goods, Performance Materials, and Technology businesses. It supports clients with sourcing, market insights...

DKSH Buys Global Rights to Roche’s Rocephin to Bolster Healthcare Own Brands

Oct 28, 2026

DKSH has acquired from Roche the rights to Rocephin, a broad-spectrum antibiotic whose active ingredient ceftriaxone is on the World Health Organization’s Model List of Essential Medicines, across more than 80 markets in Asia Pacific, Europe, Africa,...

DKSH Buys NewBridge to Build Middle East Healthcare Platform

Oct 19, 2026

DKSH has agreed to acquire 100% of Dubai-headquartered NewBridge Pharmaceuticals for an enterprise value of USD 390 million, establishing a healthcare commercialization platform in the Middle East and North Africa. The deal extends DKSH Healthcare’s...

DKSH Expands Grünenthal Pain Management Partnership Across Eight Asia-Pacific Markets

Sep 28, 2026

DKSH’s Healthcare unit has expanded its collaboration with Grünenthal, a global leader in pain management, to commercialize four specialty pain medicines across up to eight Asia-Pacific markets. The agreement builds on an existing relationship and un...

DKSH to Bolster Southeast Asia Pharma Footprint with Acquisition of Thailand’s P.R. Chemicals

Aug 27, 2026

DKSH Performance Materials has signed an agreement to acquire Thailand-based P.R. Chemicals, a long-established distributor of Active Pharmaceutical Ingredients serving more than 100 pharmaceutical customers across diverse therapeutic areas. Founded...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 17, 2026